Currently, there is an increase in complications of refractive errors, mainly myopia. One of the complications is myopic choroidal neovascularization (MCNV). The aim of the study is to improve the treatment of HCNV using anti–VEGF therapy according to the “treat-and-extend” scheme.

Materials and Methods. The study included 34 patients (34 eyes) with MCNV who received intravitreal injections of Brolucizumab. Best corrected visual acuity (BCVA), central retinal thickness (CST) and OCT parameters (subretinal fluid (SRF) height and choroidal neovascularization volume) dynamics were assessed using standard ophthalmological methods at 1, 3, 6, and 12 months. Results. The mean BCVA improved to 0.60±0.07 after 12 months (p<0.05), the mean CST decreased to 324,05±14,1 µm (p<0.05) and the subretinal fluid (SRF) height decreased from 163.16 ± 12.09 μm at baseline to 87.43 ± 16.43 μm after 12 months (p=0.05).Whereas in the control group, after 12 months, BCVA increased to 0.54 ± 0.06 , CST decreased to 320,12±12,4 μm and the SRF height decreased to 112.11 ± 12.23 μm after 12 months. Furthermore, in the main group, the choroidal neovascularization volume decreased from 2.7±0,1 mm³ to 1.3±0,06 mm³ following a 12-month course of treatment. In the control group, this indicator decreased slightly to 1.4±0,07 mm³ (compared to a baseline of 2.7±0,1 mm³). Conclusions. Anti-VEGF therapy for MCNV demonstrates high efficacy, especially the "treat-and-extend" regimen minimizes the number of injections while ensuring a stable therapeutic effect.

Myopic choroidal neovascularization, anti-VEGF therapy, Brolucizumab, treat-and-extend

Fayzrakhmanov R.R. Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice. Russian Ophthalmological Journal. 2019;12(2):97-

(in Russ.) https://doi.org/10.21516/2072-

-2019-12-2-97-105

Markosian G.A., Tarutta E.P., Tarasova N.A., Maximova M.V. The fundus changes in pathological myopia. Russian Journal of Clinical Ophthalmology. 2019;19(2):99-104. (in Russ.)

https://doi.org/10.32364/2311-7729-2019-19-2-99-104

Makogon S.I., Kuznetsova E.N. Myopic Choroidal Neovascularization: Questions Regarding Patient Management Remain. Acta biomedica scientifica. 2021; 6(6-1): 74-81. (in Russ.)

https://doi.org/10.29413/ABS.2021-6.6-1.9

Kurysheva N.I., Sergushev S.G., Naumova V.I., Ivanova A.A. Evolution of the use of angiogenesis inhibitors in ophthalmology. Effective Pharmacotherapy. 2022; 18 (11): 58–67. (in Russ.) https://doi.org/10.33978/2307-3586-2022-18-11-58-67

Korotkikh S.A., Bobykin E.V., Nazarova N.S., Melekhina E.E. Long-term outcomes of anti-angiogenic therapy for macular neovascular disorders. Russian Annals of Ophthalmology. 2016;132(1):76‑84.(in Russ.)

https://doi.org/10.17116/oftalma2016132176-84

Zenkova E.S., Myagkov A.V., Ignatova N.V., Zhabina

O.A. Medical technology for the management of myopia progression. The EYE GLAZ. 2024;26(1):49-

(in Russ.) https://doi.org/10.33791/2222-4408-2024-1-49-55

Wong T.Y, Ohno-Matsui C, Lanzetta M. Myopic choroidal neovascularization: Current concepts and update on anti-VEGF therapy. British Journal of Ophthalmology.2015;99(3):289–296. https://doi.org/ 10.1136 /bjophthalmol-2014-

Wolf S, Balciuniene M, Laganovska J. RADIANCE: A study of ranibizumab for myopic choroidal neovascularization. Ophthalmology. 2014;121, (3) :

–692.

https://doi.org/10.1016/j.ophtha.2013.10.023.

Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik J.F, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi

T. MYRROR Investigators. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology. 2015 Jun;122(6):1220-7. https://doi.org/10.1016/j.ophtha.2015.01.025

El Matri L, Chebil A, Kort F. Current and emerging treatment options for myopic choroidal neovascularization. Clin Ophthalmol. 2015;9:733-744. https://doi.org/10.2147/OPTH.S49437